NGNE Neurogene Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NGNE

Price (delayed)

$36.1

Market cap

$463.99M

P/E Ratio

1.3

Dividend/share

N/A

EPS

$27.76

Enterprise value

$331.53M

neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed ...

Highlights
NGNE's equity has soared by 147% QoQ
NGNE's EPS has soared by 121% QoQ and by 120% YoY
Neurogene's net income has increased by 34% YoY but it has decreased by 14% QoQ
NGNE's debt has surged by 52% since the previous quarter
NGNE's quick ratio is down by 43% from the previous quarter and by 30% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://neoleukin.com
Peers: OMER OMGA

Key stats

What are the main financial stats of NGNE
Market
Shares outstanding
12.85M
Market cap
$463.99M
Enterprise value
$331.53M
Valuations
Price to earnings (P/E)
1.3
Price to book (P/B)
0.46
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$36.31M
EBITDA
-$32.35M
Free cash flow
-$51.74M
Per share
EPS
$27.76
Free cash flow per share
-$105.2
Book value per share
$79.18
Revenue per share
$0
TBVPS
$452.51
Balance sheet
Total assets
$222.57M
Total liabilities
$36.55M
Debt
$16.26M
Equity
$186.02M
Working capital
$177.38M
Liquidity
Debt to equity
0.09
Current ratio
8.72
Quick ratio
8.6
Net debt/EBITDA
4.1
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-28.8%
Return on equity
-34.4%
Return on invested capital
-53.1%
Return on capital employed
-18.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NGNE stock price

How has the Neurogene stock price performed over time
Intraday
2.01%
1 week
20.49%
1 month
-17.84%
1 year
105.11%
YTD
86.27%
QTD
-29.08%

Financial performance

How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$55.58M
Net income
-$36.32M
Gross margin
N/A
Net margin
N/A
NGNE's operating income has dropped by 57% since the previous quarter
Neurogene's net income has increased by 34% YoY but it has decreased by 14% QoQ

Growth

What is Neurogene's growth rate over time

Valuation

What is Neurogene stock price valuation
P/E
1.3
P/B
0.46
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS has soared by 121% QoQ and by 120% YoY
NGNE's equity has soared by 147% QoQ
The stock's price to book (P/B) is 74% less than its 5-year quarterly average of 1.7 but 13% more than its last 4 quarters average of 0.4

Efficiency

How efficient is Neurogene business performance
The ROE has soared by 76% from the previous quarter and by 68% YoY
The company's return on invested capital has surged by 51% YoY and by 3.6% QoQ
NGNE's return on assets is up by 32% year-on-year and by 12% since the previous quarter

Dividends

What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NGNE.

Financial health

How did Neurogene financials performed over time
Neurogene's total liabilities has soared by 155% from the previous quarter
The total assets has soared by 148% from the previous quarter and by 104% YoY
NGNE's debt is 91% smaller than its equity
NGNE's equity has soared by 147% QoQ
NGNE's debt has surged by 52% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.